LENZ Therapeutics Reports Third Quarter 2026 Financial Results, Announces Strategic Consumer Marketing Focused Reorganization and CEO Succession
Telehealth contributed more than 50% of incremental quarterly prescriptions as LENZ shifts resources toward consumer marketing.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
LENZ Therapeutics (LENZ) reported third-quarter VIZZ product sales of $2.6 million and announced a reorganization focused on consumer marketing. Sales increased 50% over the prior quarter, with over 38,000 paid prescriptions. Total revenue was $3.384 million versus $12.5 million a year earlier, while net loss widened to $31.0 million from $16.7 million.
The company expects the reorganization to reduce projected 2027 annualized operating expenses by more than 50%, targeting approximately $70 million to $75 million, excluding stock-based compensation. It anticipates substantially completing the work in Q4 2026, with estimated one-time net restructuring charges of $5 million. CFO Dan Chevallard will become interim president and CEO on December 1, 2026, succeeding Eef Schimmelpennink, who will remain a strategic advisor into 2027. Cash, cash equivalents and marketable securities totaled $197.3 million at September 30, 2026.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Major point. Forward-looking: it has not happened yet and may not happen.LENZ expects more than 50% lower projected 2027 annualized operating expenses through its reorganization.
- Moderate pointVIZZ Q3 product sales reached $2.6 million, up 50% over Q2 2026.
- Moderate pointQ3 paid prescriptions exceeded 38,000, increasing approximately 51% over Q2 2026.
- Moderate pointR&D expenses were zero for Q3 and nine months, versus $3.8 million and $18.7 million in 2025.
- Minor pointTelehealth contributed more than 50% of incremental prescriptions in Q3 2026 over Q2 2026.
7 minor points
- Minor pointRepeat purchases exceeded 60% of ePharmacy patients since launch.
- Minor pointAverage refills were five packs per year among patients starting VIZZ in Q4 2025 and Q1 2026.
- Minor pointUnique prescribers exceeded 15,000 through Q3 2026, with over 75% prescribing multiple times.
- Minor point. Forward-looking: it has not happened yet and may not happen.Reorganization targets approximately $70 million to $75 million in 2027 operating expenses, excluding stock-based compensation.
- Minor pointVIZZ regulatory applications were submitted in Saudi Arabia, Malaysia and Vietnam, bringing ex-U.S. filings to eleven.
- Minor pointNine-month product sales reached $6.0 million, compared with no product sales in the same 2025 period.
- Minor pointTotal liabilities declined to $17.750 million at September 30, 2026, from $21.537 million at December 31, 2025.
Negative
- Major pointQ3 net loss widened to $31.0 million, or $0.99 per share, versus $16.7 million, or $0.59, a year earlier.
- Moderate pointQ3 total revenue fell to $3.384 million from $12.5 million a year earlier.
- Moderate pointQ3 selling, general and administrative expenses increased to $35.8 million from $27.6 million a year earlier.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Reorganization carries estimated $5 million in one-time net restructuring charges. 5.1% of market cap
- Minor pointNine-month net loss widened to $104.4 million, or $3.33 per share, versus $46.2 million, or $1.65, in 2025.
7 minor points
- Minor pointNine-month total revenue fell to $10.771 million from $17.5 million in 2025.
- Minor pointQ3 license revenue declined to $0.785 million from $12.5 million a year earlier.
- Minor pointNine-month license revenue declined to $4.785 million from $17.5 million in 2025.
- Minor pointNine-month selling, general and administrative expenses increased to $120.2 million from $51.5 million in 2025.
- Minor pointCost of sales totaled $0.454 million in Q3 and $1.810 million over nine months, versus none in 2025.
- Minor pointTotal assets fell to $209.749 million at September 30, 2026, from $305.876 million at December 31, 2025.
- Minor pointStockholders’ equity fell to $191.999 million at September 30, 2026, from $284.339 million at December 31, 2025.
Details
Market move: LENZ -11.21% vs previous close. Q3 2026 earnings report
On Oct 28, the day this news came out, the latest delayed price for LENZ is 11.21% below the previous close. Argus tracked a trough of -13.4% from its starting point during tracking. Our momentum scanner has recorded 3 alerts for this stock so far that day. The latest delayed price is $2.85.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Q3 VIZZ product sales
- $2.6 million
- Three months ended September 30, 2026
- Paid prescriptions
- Over 38,000
- Q3 2026
- Product sales growth
- 50%
- Q3 2026 over Q2 2026
- Projected operating expense reduction
- More than 50%
- Projected 2027 annual operating expenses
- Projected operating expenses
- $70 million to $75 million
- 2027 target, excluding stock-based compensation
- Net restructuring charges
- $5 million
- One-time estimated charges
- Cash, cash equivalents and marketable securities
- $197.3 million
- As of September 30, 2026
- Net loss
- $31.0 million
- Three months ended September 30, 2026
Previous Earnings Reports
-
Q2 VIZZ sales were $1.7 million, establishing the sequential sales baseline for Q3's reported growth.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
presbyopia medical
maa regulatory
sg&a financial
miotic medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Q3 2026 VIZZ® product sales increased
Strategic reorganization to prioritize consumer marketing, support the continued market expansion of VIZZ and reduce projected 2027 annual operating expenses by over
Eef Schimmelpennink to transition from his role as President and Chief Executive Officer effective December 1, 2026; Dan Chevallard appointed Interim President and Chief Executive Officer
Management to host conference call on October 29, 2026, at 8:30 a.m. EDT
SAN DIEGO, Oct. 28, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmic solution)
“Our strong third-quarter results demonstrate continued progress in the commercialization of VIZZ, with product sales growth of
Mr. Schimmelpennink continued, “After nearly six years leading LENZ and more than 25 years in the biotechnology industry, I have decided to transition from my role as CEO effective December 1, 2026, to devote more time to other passions. I am very proud of the team we have built, the culture we have created and the successes we have achieved together. I am deeply grateful to our employees, the Board and our shareholders for their support. I believe as strongly as ever in LENZ’s future and have full confidence in Dan’s ability to lead the company. Dan and I will work closely to ensure a smooth handover, and I look forward to continuing to support him and the Board as a strategic advisor following the CEO transition.”
“We are deeply grateful to Eef for his leadership in building LENZ from our Series A into a well-capitalized public company and advancing VIZZ through clinical development, FDA approval and commercial launch. We wish him all the best for the future,” said Jeff George, Chairman of the Board of Directors of LENZ Therapeutics. “Dan brings a deep understanding of LENZ and our operating priorities and has our full confidence to lead the company as Interim CEO, with continued support from Eef and the Board through the transition. We are confident in the opportunity ahead for VIZZ and in our team’s ability to execute the more focused commercial strategy announced today.”
“I am grateful to Eef for his leadership and contributions to LENZ and look forward to building on the solid foundation we have established,” said Dan Chevallard, Chief Financial Officer and incoming Interim Chief Executive Officer of LENZ Therapeutics. “I am honored to lead LENZ through this next phase. Our priorities are clear: drive continued increases in consumer awareness, access and adoption of VIZZ and deploy our resources with discipline. I firmly believe in VIZZ’s potential and our team’s ability to deliver on these priorities.”
Third Quarter 2026 and Recent Corporate Highlights
Commercial Update
- Q3 2026 product sales of
$2.6 million on over 38,000 paid prescriptions, representing increases of approximately50% and51% over Q2 2026, respectively, with meaningful prescription growth observed across both the ePharmacy and retail distribution channels and momentum continuing into Q4. - In July 2026, the Company launched a telehealth prescribing option to accelerate patient access to VIZZ, offering patients the convenience of an integrated online evaluation by independent licensed eye care providers, ePharmacy prescription fulfillment, and home delivery, in addition to existing access through eye care professionals. The telehealth channel contributed more than
50% of the incremental prescriptions in Q3 2026 over Q2 2026. - Over
60% of ePharmacy patients have purchased more than one monthly pack of VIZZ since launch, confirming continued encouraging average refill rates from those starting VIZZ in Q4 2025 and Q1 2026 of five packs per year. - Continued growth among prescribing eye care professionals (“ECPs”), with over 15,000 unique prescribers from launch through Q3 2026, with over
75% prescribing multiple times. - In July 2026, the Company launched a nationwide TV advertising campaign and optimized its targeted digital consumer marketing, with an increased focus on those commercial activities most efficiently driving consumer awareness, adoption and new patient acquisition.
Strategic Reorganization
- Announced a strategic reorganization, implemented in Q4 2026, to streamline the organization and prioritize resources and capital on the initiatives expected to have the highest impact on sales. The reorganization is expected to enable LENZ to operate with a more focused and efficient organizational structure while retaining the capabilities necessary to support the continued commercialization of VIZZ.
- The Company expects the reorganization to reduce projected 2027 annualized operating expenses by more than
50% , targeting approximately$70 million to$75 million in 2027 operating expenses, excluding stock-based compensation. - Substantially all activities related to the strategic reorganization are anticipated to be completed during Q4 2026 with an estimated
$5 million in one-time net restructuring charges.
Leadership Transition
- Eef Schimmelpennink, President and Chief Executive Officer, will transition from his role effective December 1, 2026. Dan Chevallard, currently Chief Financial Officer, has been appointed Interim President and Chief Executive Officer, effective December 1, 2026. Mr. Schimmelpennink will lead the organization through the reorganization and support a seamless leadership transition by continuing to serve as a strategic advisor to the Company into 2027.
Global Regulatory and Commercialization Update
- In July 2026, under the exclusive distribution agreement with Lunatus for the Middle East region, the MAA was submitted under the Saudi Food and Drug Authority’s Abridged Pathway for the treatment of presbyopia in the Kingdom of Saudi Arabia. This submission represents the ninth ex-U.S. regulatory filing for VIZZ.
- In August and September 2026, under the licensing and commercialization agreement with Lotus Pharmaceutical, the MAA was submitted for the treatment of presbyopia in Malaysia and Vietnam, respectively. This represents the fifth and sixth submissions for approval under the agreement, and tenth and eleventh ex-U.S. regulatory filings for VIZZ, respectively.
Financial Results for Three and Nine Months Ended September 30, 2026
Cash Position: Cash, cash equivalents and marketable securities were
Product Sales, net: Product sales, net was
License Revenue: License revenue was
Cost of Sales: Cost of sales was
Selling, General and Administrative (“SG&A”) Expenses: SG&A expenses increased to
Research and Development (“R&D”) Expenses: There were no R&D expenses for the three and nine months ended September 30, 2026, compared to
Net Loss: Net loss for the three and nine months ended September 30, 2026 was
Conference Call Information
The Company will host a conference call and webcast on Thursday, October 29, 2026, at 8:30 a.m. EDT. To participate in the conference call via telephone, dial (800) 715-9871 (Domestic) or (646) 307-1963 (International) and enter code 3074036. The live webcast can be accessed here and on the LENZ Therapeutics website at www.LENZ-tx.com in the Investors & Media section. A replay of the webcast will be available on the Company’s website for 30 days following the event.
About Presbyopia
Presbyopia is the inevitable loss of near vision associated with aging, impacting the daily lives of nearly all people over the age of 45. As people age, the crystalline lens in their eyes gradually hardens and becomes less able to change shape. This loss of elasticity reduces the lens’ ability to focus incoming light from near objects onto the retina. Adults over 50 years of age lose, on average, 1.5 lines of near vision every six years. Although the progression of presbyopia is gradual, presbyopes often experience an abrupt change in their daily life as the symptoms become more pronounced starting in their mid-40s, when reading glasses or other corrective aids are suddenly necessary to read text or conduct close-up work. Presbyopia is typically self-diagnosed and self-managed with over-the-counter reading glasses, or managed, after evaluation by an ECP, with prescription reading or bifocal glasses or multifocal contact lenses.
About VIZZ (aceclidine ophthalmic solution)
VIZZ (aceclidine ophthalmic solution)
VIZZ Indication and Important Safety Information
INDICATION
VIZZ (aceclidine ophthalmic solution)
IMPORTANT SAFETY INFORMATION
- Do not use VIZZ if allergic to any of the ingredients.
- To help avoid potential eye injury or contamination of the product, do not allow the vial tip to touch the eye or any surfaces. Discard the opened vial immediately after use.
- Contact lenses should be removed before using VIZZ. After dosing, contact lenses can be reinserted after 10 minutes.
- If using more than one topical eye medication, the medicines should be administered at least 5 minutes apart.
- Temporary dim or dark vision may be experienced after using VIZZ. Do not drive or operate machinery if vision is not clear.
- Seek immediate medical care if sudden onset of flashing lights, floaters, or vision loss is experienced.
ADVERSE REACTIONS
The most common reported adverse reactions of participants were instillation site irritation (
For additional information, please see the full Prescribing Information available at http://www.VIZZ.com/full-prescribing-information.pdf.
About LENZ Therapeutics
LENZ Therapeutics is a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmic solution)
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of federal securities laws. You can identify forward-looking statements by words such as “may,” “will,” “could,” “can,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “poised,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, but not all forward-looking statements will contain these words. Forward-looking statements in this press release include statements regarding LENZ’s management transition plans and expectations; strategic reorganization plans and related expectations; the expectation that the reorganization will enable LENZ to streamline the organization and prioritize resources and capital on the highest impact initiatives designed to increase consumer awareness, access and adoption, expected restructuring charges; expectations regarding operating expenses following the restructuring; plans and expectations regarding the telehealth platform; the belief that the launch of the telehealth platform alongside LENZ’s sales and marketing activities will help accelerate consumer awareness, access and adoption of VIZZ, and the belief that LENZ is building the foundation for sustained growth driven by consumers; expectations regarding the growth among prescribing ECPs; the potential market size for VIZZ; LENZ’s commercialization plans, including international partnering plans and expectations under existing commercial arrangements; projected refill rates; and the quotations of LENZ management. These statements are based on numerous assumptions concerning VIZZ, target markets and involve substantial risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievement to be materially different from the information expressed or implied by these forward-looking statements, including those risk factors described in the section titled “Risk Factors” in our Quarterly Report on Form 10-Q filed for the quarter ended June 30, 2026, in our Quarterly Report on Form 10-Q to be filed for the quarter ended September 30, 2026 and in our subsequent filings with the SEC. We cannot assure you that the forward-looking statements in this press release or the assumptions upon which they are based will prove to be accurate. The forward-looking statements in this press release are as of the date of this press release. Except as otherwise required by applicable law, LENZ disclaims any duty to update any forward-looking statements. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.
Contact:
Dan Chevallard
LENZ Therapeutics
IR@LENZ-tx.com
| LENZ Therapeutics, Inc. Selected Balance Sheet Highlights (in thousands) | |||||
| September 30, 2026 | December 31, 2025 | ||||
| (unaudited) | |||||
| Cash and cash equivalents | $ | 30,553 | $ | 25,179 | |
| Marketable securities | 166,750 | 267,168 | |||
| Total assets | 209,749 | 305,876 | |||
| Total liabilities | 17,750 | 21,537 | |||
| Total stockholders’ equity | 191,999 | 284,339 | |||
| LENZ Therapeutics, Inc. Condensed Consolidated Statement of Operations and Comprehensive Loss (in thousands, except share and per share data) (unaudited) | |||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||
| Revenue: | |||||||||||||||
| Product sales, net | $ | 2,599 | $ | — | $ | 5,986 | $ | — | |||||||
| License revenue | 785 | 12,500 | 4,785 | 17,500 | |||||||||||
| Total revenue | 3,384 | 12,500 | 10,771 | 17,500 | |||||||||||
| Operating expenses: | |||||||||||||||
| Cost of sales | 454 | — | 1,810 | — | |||||||||||
| Selling, general and administrative | 35,848 | 27,596 | 120,186 | 51,505 | |||||||||||
| Research and development | — | 3,791 | — | 18,670 | |||||||||||
| Total operating expenses | 36,302 | 31,387 | 121,996 | 70,175 | |||||||||||
| Loss from operations | (32,918 | ) | (18,887 | ) | (111,225 | ) | (52,675 | ) | |||||||
| Other (expense) income: | |||||||||||||||
| Other (expense) income | (36 | ) | (14 | ) | (46 | ) | 174 | ||||||||
| Interest income | 1,985 | 2,201 | 6,899 | 6,770 | |||||||||||
| Total other income, net | 1,949 | 2,187 | 6,853 | 6,944 | |||||||||||
| Net loss before income taxes | (30,969 | ) | (16,700 | ) | (104,372 | ) | (45,731 | ) | |||||||
| Income tax expense | — | — | 3 | 500 | |||||||||||
| Net loss | $ | (30,969 | ) | $ | (16,700 | ) | $ | (104,375 | ) | $ | (46,231 | ) | |||
| Other comprehensive loss: | |||||||||||||||
| Unrealized (loss) gain on marketable securities | (428 | ) | 189 | (1,299 | ) | 31 | |||||||||
| Comprehensive loss | $ | (31,397 | ) | $ | (16,511 | ) | $ | (105,674 | ) | $ | (46,200 | ) | |||
| Net loss per share, basic and diluted | $ | (0.99 | ) | $ | (0.59 | ) | $ | (3.33 | ) | $ | (1.65 | ) | |||
| Weighted-average common shares outstanding, basic and diluted | 31,420,063 | 28,540,519 | 31,382,605 | 28,052,279 | |||||||||||
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How much did LENZ Therapeutics VIZZ sales grow in Q3 2026?
VIZZ product sales increased 50% over Q2 2026 to $2.6 million. Paid prescriptions exceeded 38,000, up approximately 51% over the prior quarter.
What operating expense reductions does LENZ expect from its reorganization?
LENZ expects the reorganization to reduce projected 2027 annualized operating expenses by more than 50%, targeting approximately $70 million to $75 million in 2027 operating expenses, excluding stock-based compensation. Substantially all related activities are anticipated to be completed during Q4 2026.
What contributed to LENZ Therapeutics license revenue in 2026?
Q3 license revenue included a portion of the upfront payment under the Arrotex license agreement. Nine-month license revenue also included a $2.5 million regulatory milestone under the Théa agreement, $1.25 million in sublicense revenue related to Everest Medicines’ acquisition of Greater China VIZZ rights, and the upfront payment under the Lunatus distribution agreement.
Why did LENZ Therapeutics selling, general and administrative expenses rise in 2026?
The expense increases primarily reflected VIZZ launch investment, including commercial marketing, advertising, sales infrastructure and personnel expenses from higher headcount. Non-cash stock-based compensation included in these expenses was $4.1 million for Q3 and $12.8 million for nine months, versus $3.2 million and $7.2 million in the corresponding 2025 periods.